Noch keine Produkte im Warenkorb.
Ihre Vorteile:
versandkostenfreie Lieferung
aller Studien u. Marktanalysen
oder per Kreditkarte
Bestell- und Beratungshotline
Gerne helfen wir Ihnen kostenfrei bei der Recherche nach Studien und Marktanalysen:
Tel.: +49 (0)221 168 262 42
E-Mail: service[at]marktforschung.de
Aktuelle Meldungen aus dem Ressort Studien / Marktanalysen:
15.07.10 Kooperation im Vertrieb – wer nicht kooperiert, verliert!
Köln - Wer viel Zeit und Geld hat, der wird in der Wirtschaft alles möglichst alleine machen...
28.06.10 Marktstudie Augenoptik: Die Augenoptikbranche stemmt sich erfolgreich gegen die Wirtschaftskrise
Neuwied - Der deutsche Optikmarkt hat sich zum normalen Konsumgütermarkt entwickelt und seinen...
17.06.10 Marktstudie Elektro-Kleingeräte: Branche im Aufwind
Neuwied - 2009 erreichte der Markt für Elektro-Kleingeräte mit einem Plus von 3,3 Prozent auf 3,4...
Benutzer Anmeldung
Regelmäßig Informationen über neue Studien und Spezialangebote im Shop im kostenlosen E-Mail-Abo.
Mehr Infos? Hier klicken.
Frauenkrankheiten (Gynäkologie)
Studien / Marktanalysen aus der Kategorie Frauenkrankheiten (Gynäkologie)
| Titel | ||
|---|---|---|
Italy Pharmaceutical Market Overview Generic penetration set to riseVon: Datamonitor
|
7 / 2010 |
7.980,01 € ( 11.400,00 $) |
|
Introduction |
||
Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts to 2016Von: GlobalData
|
5 / 2010 |
1.400,00 € ( 2.000,00 $) |
|
Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts to 2016 |
||
Emergency Contraception - BulgariaVon: Euromonitor
|
5 / 2010 |
675,00 € |
|
Emergency contraception sales in Bulgaria reached BGN1 million in 2009. This growth was driven by Escapelle, a product of the Hungarian company Richter Gedeon Ltd, launched in 2007. The launch was supported by a massive marketing campaign, which included television, radio, billboard and magazine advertisements and various sponsorships. This not only successfully popularised the product but also created consumer awareness of emergency c... |
||
Emergency Contraception - IranVon: Euromonitor
|
5 / 2010 |
337,00 € |
|
Emergency contraception recorded value sales of IRR410mn in 2009. It showed current value growth of 55% over the previous year, largely because the product is growing from a small base and retails at a high unit price. It showed good growth as a result of higher demand for this kind of product due to a change in cultural and sexual behaviour of Iranians, particularly the younger generation. |
||
Emergency Contraception - UkraineVon: Euromonitor
|
5 / 2010 |
675,00 € |
|
In 2009 in value terms the sales of emergency contraception increased by 39% to UAH11 million. Demand for this kind of medicine is not elastic. Moreover, the rising price of condoms (mainly imported) led to a rising number of unplanned pregnancies. Thus the demand for emergency contraception also had a positive rate of growth in 2009. |
||
Women’s Infertility - Drug Pipeline Analysis and Market Forecasts to 2016Von: GlobalData
|
4 / 2010 |
1.400,00 € ( 2.000,00 $) |
|
Women’s Infertility - Drug Pipeline Analysis and Market Forecasts to 2016 |
||
Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016Von: GlobalData
|
4 / 2010 |
1.400,00 € ( 2.000,00 $) |
|
Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016 |
||
Abnormal Uterine Bleeding Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Abnormal Uterine Bleeding Therapy Area Pipeline Report contains detailed information on the abnormal uterine bleeding drug pipeline. This report provides insight into the pipeline status of abnormal uterine bleeding drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Dysmenorrhea Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Dysmenorrhea Therapy Area Pipeline Report contains detailed information on the dysmenorrhea drug pipeline. This report provides insight into the pipeline status of dysmenorrhea drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Endometriosis Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Endometriosis Therapy Area Pipeline Report contains detailed information on the endometriosis drug pipeline. This report provides insight into the pipeline status of endometriosis drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Female Sexual Dysfunction Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Female Sexual Dysfunction Therapy Area Pipeline Report contains detailed information on the female sexual dysfunction drug pipeline. This report provides insight into the pipeline status of female sexual dysfunction drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Infertility Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Infertility Therapy Area Pipeline Report contains detailed information on the infertility drug pipeline. This report provides insight into the pipeline status of infertility drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Menopausal Symptoms Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Menopausal Symptoms Therapy Area Pipeline Report contains detailed information on the menopausal symptoms drug pipeline. This report provides insight into the pipeline status of menopausal symptoms drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Vaginal Infections Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Vaginal Infections Therapy Area Pipeline Report contains detailed information on the Vaginal Infections drug pipeline. This report provides insight into the pipeline status of Vaginal Infections drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Emergency Contraception - FranceVon: Euromonitor
|
4 / 2010 |
675,00 € |
|
In 2009, sales of emergency contraception increased by 9% in current value terms, to reach EUR10mn. Demand for emergency contraception remained high, but the 2009 growth rate was lower than 2008. The extensive communication campaign undertaken by the French government and different organisations such as INPES (National Institute for Health Prevention and Education) increased public awareness of STDs (sexually transmitted diseases) and A... |
||
Emergency Contraception - SpainVon: Euromonitor
|
4 / 2010 |
675,00 € |
|
In 2009 the Spanish Government decided to allow sales of emergency contraception on an OTC basis. However, the fact the there are 17 different regions which are in charge of implementing this new law has resulted in Catañuña being the only region to actual sell these products OTC. Sales of emergency contraception products thus reached a value of just EUR0.8 million in 2009. |
||
Emergency Contraception - DenmarkVon: Euromonitor
|
4 / 2010 |
675,00 € |
|
In 2009, value sales of emergency contraception reached DKr11 million, up 3% in current terms on the previous year. Rising consumer awareness of the products’ existence and greater mistrust of the effectiveness of condoms are driving demand. Consumer trust is a key growth driver, and the longer emergency contraception stays successfully on the market, the more women will begin to trust such products and will use them when they think the... |
||
Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continuesVon: Datamonitor
|
3 / 2010 |
5.320,01 € ( 7.600,00 $) |
|
Introduction |
||
Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016Von: GlobalData
|
2 / 2010 |
1.400,00 € ( 2.000,00 $) |
|
Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016 |
||
Pipeline Insight: Endometriosis - New therapies near market while more innovative targets still neededVon: Datamonitor
|
12 / 2009 |
7.980,01 € ( 11.400,00 $) |
|
Introduction |
||
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor typesVon: Datamonitor
|
9 / 2008 |
7.980,01 € ( 11.400,00 $) |
|
Introduction |
||
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor typesVon: Datamonitor
|
9 / 2008 |
7.980,01 € ( 11.400,00 $) |
|
Introduction |
||
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demandVon: Datamonitor
|
6 / 2008 |
2.660,00 € ( 3.800,00 $) |
|
Introduction |
||
Kidneys and Genito-Urinary System Urinary IncontinenceVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Kidneys and Genito-Urinary System Urinary Incontinence ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Metabolic Endocrinology HypogonadismVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Metabolic Endocrinology Hypogonadism ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health ContraceptionVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Women's Health Contraception ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health DysmenorrheaVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Women's Health Dysmenorrhea ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health EndometriosisVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Women's Health Endometriosis ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Female Sexual DysfunctionVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Women's Health Female Sexual Dysfunction ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health InfertilityVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Women's Health Infertility ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Labor and DeliveryVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Women's Health Labor and Delivery ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Menopausal SymptomsVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Women's Health Menopausal Symptoms ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Postmenopausal OsteoporosisVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Women's Health Postmenopausal Osteoporosis ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Women's Health Vaginal InfectionsVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Women's Health Vaginal Infections ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
*Unser Angebot richtet sich an gewerbliche Kunden, daher sind alle Preise netto ausgewiesen.
In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%).
Der korrekte Gesamtendpreis wird Ihnen nach Angabe Ihrer Rechnungsadresse im weiteren Bestellablauf ausgewiesen.

